Supplement

Beta-Glucans

Soluble beta-glucan

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

3-6

watchEffect Window

2-12 weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Beta-glucans are source-specific fibers, with oat beta-glucan having the clearest human evidence for lowering LDL cholesterol in hypercholesterolemic adults.

Oat beta-glucan has the strongest human data for lowering LDL and total cholesterol, while yeast and mushroom beta-glucans should not be assumed to share the same metabolic effects. Postprandial glucose and immune outcomes depend heavily on source and formulation.

Soluble fiber increases viscosity and slows nutrient transit, improving metabolic handling in validated contexts.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • LDL-C reduction
  • Reduced postprandial glucose excursions

Secondary Outcomes

  • Satiety and bowel regularity support
  • Limited, inconsistent inflammatory outcomes

Safety

Contraindications and Interactions

Contraindications

  • Severe motility disorders
  • Active bowel obstruction
  • Unmonitored severe malabsorption conditions

Side effects

  • Bloating
  • Gas
  • Stool inconsistency

Interactions

  • Oral medication absorption timing
  • High-dose other fiber products
  • GI-active supplements

Avoid if

  • Sensitive bowel conditions
  • Multiple high-viscosity fibers simultaneously
  • Unverified low-viscosity mislabeled products

Evidence

Study-level References

beta-glucans-SRC-001Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Yu J, Xia J, Yang C, et al. Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2022;14(10):2043. doi:10.3390/nu14102043. PMID:35631184.

Population: Hypercholesterolemic adults across 13 randomized controlled trials of oat beta-glucan.

Dose protocol: Oat beta-glucan across 13 randomized hypercholesterolemia trials

Key findings: Lowered total cholesterol and LDL cholesterol, with no meaningful effect on HDL or triglycerides.

Notes: Best current anchor for metabolic claims is oat beta-glucan specifically.

Paper content

This 2022 meta-analysis is the clearest anchor for cereal beta-glucans. In hypercholesterolemic adults, oat beta-glucan lowered total cholesterol and LDL cholesterol without meaningfully changing HDL or triglycerides. That supports a tighter supplement description focused on cholesterol lowering rather than broad claims about every metabolic or GI endpoint.

beta-glucans-SRC-002Systematic review
Sourceopen_in_new

PMID: 27724985

Population: Adults with varied metabolic risk

Dose protocol: 3-10 g/day soluble glucan preparations

Key findings: Directional improvement in satiety and glycemic control, less consistency for secondary inflammation outcomes.

Notes: Mixed formulations and dietary co-interventions.

Paper content

Directional improvement in satiety and glycemic control, less consistency for secondary inflammation outcomes.

beta-glucans-SRC-003Systematic review and meta-analysis
Sourceopen_in_new

Zheng R, Zhang H, Hua H, Zhang Y, Jin C, Zhou Y, Shi X, Zhu L. Cereal beta-glucan and cardiovascular disease risk reduction in overweight and obese populations: a systematic review and meta-analysis. Food Funct. 2026;17(1):70-88. doi:10.1039/d5fo03598h. PMID:41362998.

Population: Overweight and obese individuals (BMI 25 or higher) from 49 eligible studies.

Dose protocol: Cereal beta-glucan across 49 studies in overweight and obese populations (n=3854)

Key findings: Reduced total cholesterol by 0.24 mmol/L and LDL by 0.19 mmol/L. Oat beta-glucan lowered systolic blood pressure by 1.38 mmHg. No effects on triglycerides, HDL, or body weight.

Notes: Largest meta-analysis to date focused on overweight and obese populations. Strengthens the cholesterol-lowering claim for cereal beta-glucan.

Paper content

This large meta-analysis of 49 studies (3,854 subjects) found that cereal beta-glucan reduced total cholesterol by 0.24 mmol/L and LDL cholesterol by 0.19 mmol/L in overweight and obese populations. Oat beta-glucan also lowered systolic blood pressure by 1.38 mmHg. No significant effects were seen for triglycerides, HDL cholesterol, diastolic blood pressure, body weight, or BMI. The results support cereal beta-glucan as a cardiovascular disease prevention strategy in overweight populations.

beta-glucans-SRC-004Double-blind, randomized, placebo-controlled trial
Sourceopen_in_new

Dharsono T, Rudnicka K, Wilhelm M, Schoen C. Effects of Yeast (1,3)-(1,6)-Beta-Glucan on Severity of Upper Respiratory Tract Infections: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Subjects. J Am Coll Nutr. 2019;38(1):40-50. doi:10.1080/07315724.2018.1478339. PMID:30198828.

Population: Generally healthy adults with a history of frequent upper respiratory infections.

Dose protocol: 900 mg daily yeast beta-glucan (1,3/1,6) for 16 weeks during winter

Key findings: Significantly reduced severity of physical URTI symptoms during the first week of infection versus placebo. Global severity across full infection episodes was not significantly different.

Notes: Supports the immune modulation framing for yeast-derived beta-glucans specifically.

Paper content

This 16-week double-blind RCT in 299 healthy adults found that 900 mg daily yeast beta-glucan (1,3/1,6) significantly reduced the severity of physical upper respiratory tract infection symptoms during the first week of illness compared with placebo. Global severity across the full infection episode was not significantly different, but early-phase symptom reduction and mood improvements were notable. The study supports a role for yeast beta-glucan in moderating URTI symptom burden.

beta-glucans-SRC-005Randomized double-blind cross-over pilot trial
Sourceopen_in_new

Iman Y, Dandeneau D, Wang H, Mollard R, Whitlock R, Ames N, Malunga L, Tangri N, Mackay D, Netticadan T, Thandapilly SJ. Effect of oat beta-glucan in managing blood pressure: a randomized cross-over pilot trial. Appl Physiol Nutr Metab. 2025;50:1-9. doi:10.1139/apnm-2024-0317. PMID:41031804.

Population: Middle-aged and older adults with mild hypertension.

Dose protocol: 4 g/day high-molecular-weight oat beta-glucan in breakfast cookies for 4 weeks

Key findings: Did not reduce systolic or diastolic blood pressure versus wheat-based control in adults with mild hypertension.

Notes: Useful modern null trial that keeps the cardiovascular evidence focused on lipids rather than assuming a blood-pressure effect.

Paper content

This randomized double-blind cross-over pilot trial tested whether 4 g/day of high-molecular-weight oat beta-glucan could reduce blood pressure in adults with mild hypertension. Twenty-one participants completed 4-week treatment and control phases using oat or wheat breakfast cookies. The intervention did not lower systolic or diastolic blood pressure and did not materially change heart rate, body weight, waist circumference, or dietary intake. The result is important because it narrows the cardiovascular interpretation of oat beta-glucan to lipid lowering rather than assuming a reliable antihypertensive effect.

Guides

Setup

Help